Table 2.
Characteristics of study subjects
| HIV monoinfected N=1990 | HIV-HBV co-infected N=115 | P | |
|---|---|---|---|
| Age (IQR) (years)* | 34 (29–40) | 34 (30–40) | 0.53 |
| Male sex (%) | 39 | 47 | 0.09 |
| Race | 0.07 | ||
| Black (%) | 62.1 | 73.9 | |
| White (%) | 12.5 | 2.6 | |
| Asian (%) | 16.9 | 18.2 | |
| Other (%) | 7.5 | 5.2 | |
| BMI (IQR)* | 22.4 (20.3–25.3) | 21.7 (19.8–24.0) | 0.02 |
| ALT (IQR)* (U/L) | 23 (16.5–35.0) | 25.5 (19.0–38.0) | 0.03 |
| Normal | 1804 (91.0%) | 100 (87.0%) | 0.14 |
| Mild | 154 (7.8%) | 11 (9.6%) | |
| Moderate | 20 (1.0%) | 4 (3.5%) | |
| Severe | 3 (0.2%) | 0 (0.0%) | |
| Life Threatening | 1 (0.01%) | 0 (0.0%) | |
| AST (IQR)* (U/L) | 28.8 (23.0–38.0) | 34 (27.0–44.0) | <0.001 |
| Normal | 1703 (85.9%) | 86 (74.8%) | 0.001 |
| Mild | 242 (12.2%) | 28 (24.3%) | |
| Moderate | 35 (1.8%) | 1 (0.9%) | |
| Severe | 2 (0.1%) | 0 (0.0%) | |
| Life Threatening | 1 (0.1%) | 0 (0.0%) | |
| HIV characteristics | |||
| CD4 T-cell count (IQR) (cells/mm3)* | 159 (90,218) | 137 (68,210) | 0.04 |
| HIV RNA (IQR) (log cp/ml)* | 5.1 (4.6–5.5) | 5.1 (4.6–5.6) | 0.23 |
| WHO Stage IV or clinical AIDS (%) | 8.6 | 12.2 | 0.19 |
*
median values